After 30 Years, the Company Responsible for Improving Millions of Titanium Implants Finally Has Something to Say

OLD BETHPAGE, N.Y., June 25, 2021 /PRNewswire/ — For three decades, Long Island-based Himed has changed the way patients respond to dental and orthopedic implants. But they’ve always avoided self promotion, until a new CEO arrived.

  • Himed was born at the back of a metal coatings company in New York
  • Over 30 years, they quietly developed surface treatment technologies for dental and orthopedic implants that are now used worldwide by millions of patients
  • Before hiring their new CEO, most of Himed’s innovations flew under the radar, and all business was acquired through word of mouth.
  • The publication of their 30 year history is part of an overall push to gain visibility for the company’s achievements

Millions of people are living with dental and medical implants that technology from Himed made possible—but few know Himed’s name. This week, Himed is publishing its story, which covers how they went from a one-room operation at the back of an aerospace coatings factory to a global biomaterials manufacturer.

In 1991, implant manufacturers didn’t have the supply chain they do today, so asking a factory that specialized in high performance surfaces to put a textured finish on hip implants wasn’t nearly as odd as it sounds. Himed’s co-founder, Ed Garofalo answered one such request, which only led to an even more unusual request concerning hydroxyapatite, the primary mineral component found in human bone.

A hip stem (which is part of a hip replacement system) demonstrating a textured area coated in hydroxyapatite to encourage better healing. Himed offers a complete line of unique texturing and coating solutions for medical implants with its MATRIX™ line of surface treatments.

Doing their own research and experimentation, Ed and his team learned about this unique, biocompatible calcium phosphate. Not only were they among the first to discover how to plasma spray hydroxyapatite, they invented an entirely new way to use calcium phosphate materials as an abrasive on titanium. Without the risk of toxic residue that can occur with conventional alumina or silicon carbide grit, Himed’s biocompatible grit blasting technique is now used for texturizing hundreds of thousands of titanium implants annually.

Up until now, Himed has worked quietly in the background of the biomaterial and implant coatings industry, amassing discoveries and unique processes along the way. When Dana Barnard was hired as the new CEO in 2020, his first challenge was to navigate the challenges of COVID.

His next step was to share Himed’s story. It started with a build-out of the company website, followed by Himed’s first whitepaper. This week, the full story will be told with the publication of the company’s 30 year history titled Answering the Calls: 30 Years of Himed History.

About Himed: Since 1991, Himed has been on the vanguard of biomaterial coating characterization. With an all-in-one research and production facility located in the state of New York, Himed supplies raw biomaterials for a wide variety of purposes and provides highly customizable biocompatible coating and texturing solutions with their MATRIX™ line of surface treatments. Himed continues to make formative in-roads to healing technologies that greatly enhance outcomes for patients around the world.

Kaelie Barnard, Director of Marketing & Digital Strategies, Barson Corporation | 505-603-3020


Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button